Reports Q4 revenue $75.6M, consensus $63.45M. "We are pleased to report continued robust growth in our core NUZYRA commercial revenue. These results, combined with the efforts we have made to enroll patients in our NTM Phase 2b clinical study, advance regulatory discussions in Japan for NTM, and generate new efficacy data in our Project BioShield anthrax program highlight the broad utility of NUZYRA and the overall strength of our business," said Evan Loh, M.D., chief executive officer at Paratek.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on PRTK:
- Paratek Pharmaceuticals Announces Full-Year 2022 Revenue of $160.3 Million
- Paratek Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on March 16
- Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
- Paratek announces inclusion of NUZRYA in China’s NRDL
- Paratek Pharmaceuticals Announces Inclusion of NUZYRA® (omadacycline) in China’s National Reimbursement Drug List (NRDL)
